Skip to content

Sublingual Birch Immunotherapy for Pollen-associated Food Allergy

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-523653-34-00
Enrollment
96
Registered
2026-05-29
Start date
Unknown
Completion date
Unknown
Last updated
2026-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Birch pollen Allergy, Pollen-associated Food Allergy

Brief summary

Change from baseline to Visit 5 in the combined global VAS (itching, stinging, prickling within 5 minutes after apple challenge)

Detailed description

Change from baseline to Visit 5 in the combined global VAS (itching, stinging, prickling within 5 minutes after apple challenge), Change from baseline to Visit 5 in the Modified Bergmann Score, Change from baseline to Visit 5 in FAQLQ/FAIM total score, Change from baseline to Visit 5 in asthma symptoms and disease control total score (in asthmatic patients), Change from baseline to Visit 5 in RDF symptoms (in IBS subgroup), Incidence of solicited treatment-emergent local and systemic reactions (WAO grading), Incidence of unsolicited treatment-emergent AEs and SAEs, Incidence of anaphylaxis events, Physical examinations and vital signs, Use of rescue medication (Ceterizine, Prednisolon) to relief allergic symptoms as side effects, Use of emergency medication (systemic steroids, high-dose antihistamines or adrenaline) to treat side-effects of the apple challenge, Safety laboratory data, Likert Tolerability Scale Score for treatment, Change from baseline to Visit 5 in 5-point Likert Tolerability Scale Score after apple challange, Treatment adherence (days of IMP intake vs. non-intake, drug accountability)., Change from baseline to Visit 5 in systemic (serum concentrations of) total IgE, specific IgE, and IgG4 for Mal d1 and Bet v1

Interventions

DRUGITULAZAX 12 SQ-Bet Lyophilisat zur sublingualen Anwendung
DRUGINFECTODIARRSTOP® LGG® Mono Beutel Pulver zur Herstellung einer Suspension zum Einnehmen für Säuglinge und Kleinkinder Wirkstoff: Lactobacillus rhamnosus GG (LGG) gefriergetrocknet
DRUGmindestens 5 x 109 KBE
DRUGGelatine (fish
DRUGhigh molecular weight)
DRUGstandard molecular weight)
DRUGMannitol

Sponsors

Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Change from baseline to Visit 5 in the combined global VAS (itching, stinging, prickling within 5 minutes after apple challenge)

Secondary

MeasureTime frame
Change from baseline to Visit 5 in the combined global VAS (itching, stinging, prickling within 5 minutes after apple challenge), Change from baseline to Visit 5 in the Modified Bergmann Score, Change from baseline to Visit 5 in FAQLQ/FAIM total score, Change from baseline to Visit 5 in asthma symptoms and disease control total score (in asthmatic patients), Change from baseline to Visit 5 in RDF symptoms (in IBS subgroup), Incidence of solicited treatment-emergent local and systemic reactions (WAO grading), Incidence of unsolicited treatment-emergent AEs and SAEs, Incidence of anaphylaxis events, Physical examinations and vital signs, Use of rescue medication (Ceterizine, Prednisolon) to relief allergic symptoms as side effects, Use of emergency medication (systemic steroids, high-dose antihistamines or adrenaline) to treat side-effects of the apple challenge, Safety laboratory data, Likert Tolerability Scale Score for treatment, Change from baseline to Visit 5 in 5-point Likert Toler

Outcome results

None listed

Source: EU CTIS · Data processed: May 30, 2026